US4452734A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Herpes subunit vaccine
Assignee: Merck and Co Inc
•
Filing: 1982-08-11
•
Granted: 1984-06-05
•
Expires: 2002-08-11
Abstract
Abstract Herpes virus subunit antigens suitable for vaccine use are prepared by (1) treating virus-infected cells with a surfactant and varying concentrations of salt to extract and solubilize viral-directed glycoproteins, (2) fractionating the solubilized material by chromatographic procedures to enrich the viral-directed glycoproteins and to remove unwanted proteins and nucleic acids, and (3) optionally treating the subunit antigens with deoxyribonuclease and formaldehyde to assure safety.
Inventors
- 👤 Vivian M. Larson
- 👤 E. Dale Lehman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 15:49
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/245; A61K2039/555; A61K2039/55505; A61K2039/57; C; C12; C12N; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16611; C12N2710/16634; Y; Y10; Y10S; Y10S530/00; Y10S530/806; Y10S530/82; Y10S530/826
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
82 words
An antigenic, immunogenic HSV2 subunit consisting essentially of 3 groups of viral directed, membrane-bound glycoproteins which are soluble in the presence of a nonionic or anionic surfactant, the first group being from about 110,000 to about 130,000 daltons, the second group being from about 83,000 to about 90,000 daltons and the third group being from about 55,000 to about 60,000 daltons, the subunit being free of detectable DNA and being capable of inducing neutralizing antibody and of being administered as a vaccine.
Claim 2
Dependent Claim
82 words
An antigenic, immunogenic HSV2 subunit consisting essentially of 3 groups of viral directed, membrane-bound glycoproteins which are soluble in the presence of a nonionic or anionic surfactant, the first group being from about 110,000 to about 130,000 daltons, the second group being from about 83,000 to about 90,000 daltons and the third group being from about 55,000 to about 60,000 daltons, the subunit being free of detectable DNA and being capable of inducing neutralizing antibody and of being administered as a vaccine.
Claim 3
Dependent Claim
10 words
A subunit according to claim 1 having about 11 polypeptides.
Claim 4
Dependent Claim
63 words
An antigenic, immunogenic HSV1 subunit consisting essentially of two groups of viral directed membrane-bound glycoproteins which are soluble in the presence of a nonionic or anionic surfactant, the first group being about 123,000 daltons and the second group being about 60,000 daltons, the subunit being free of detectable DNA and being capable of inducing neutralizing antibody and of being administered as a vaccine.
Claim 5
Dependent Claim
63 words
An antigenic, immunogenic HSV1 subunit consisting essentially of two groups of viral directed membrane-bound glycoproteins which are soluble in the presence of a nonionic or anionic surfactant, the first group being about 123,000 daltons and the second group being about 60,000 daltons, the subunit being free of detectable DNA and being capable of inducing neutralizing antibody and of being administered as a vaccine.
Claim 6
Dependent Claim
10 words
A subunit according to claim 3 having about 9 polypeptides.
Claim 7
Dependent Claim
74 words
A process of preparing an antigenic, immunogenic, herpes virus subunit comprising infecting the cells of a tissue culture with a herpes virus capable of growing in the tissue culture, incubating the infected tissue culture until a majority of the cells exhibit cytopathic effect, contacting the infected cells with a nonionic or anionic surfactant to obtain an extract, hydrolyzing substantially all of intact double-stranded DNA in the extract, and fractionating the extract by chromatographic means.
Claim 8
Dependent Claim
74 words
A process of preparing an antigenic, immunogenic, herpes virus subunit comprising infecting the cells of a tissue culture with a herpes virus capable of growing in the tissue culture, incubating the infected tissue culture until a majority of the cells exhibit cytopathic effect, contacting the infected cells with a nonionic or anionic surfactant to obtain an extract, hydrolyzing substantially all of intact double-stranded DNA in the extract, and fractionating the extract by chromatographic means.
Claim 9
Dependent Claim
20 words
A process according to claim 5 wherein the incubation is continued until about 75% of the cells exhibit cytopathic effect.
Claim 10
Dependent Claim
17 words
A process according to claim 5 wherein the surfactant is an aryl ether adduct of ethylene oxide.
Claim 11
Dependent Claim
16 words
A process according to claim 5 wherein the extraction is effected in the presence of salt.
Claim 12
Dependent Claim
18 words
A process according to claim 8 wherein the salt concentration is from about 0.1 to about 2 molar.
Claim 13
Dependent Claim
19 words
A process according to claim 5 wherein the hydrolysis of double stranded DNA is effected by treatment with DNase.
Claim 14
Dependent Claim
13 words
A process according to claim 5 wherein the chromatographic means comprise affinity chromatography.
Claim 15
Dependent Claim
15 words
A process according to claim 11 wherein the affinity chromatography is effected by a lectin.
Claim 16
Dependent Claim
17 words
A process according to claim 12 wherein the lectin is removed by treatment with a polymerized dextran.
Claim 17
Dependent Claim
12 words
A process according to claim 5 the chromatographic means comprise anion-exchange chromatography.
Claim 18
Dependent Claim
14 words
A process according to claim 14 wherein the anion-exchange chromatography is effected by DEAE-cellulose.
Claim 19
Dependent Claim
24 words
A process according to claim 5 wherein the fractionated extract is adsorbed on alum and the adsorbed extract is washed to remove unbound surfactant.
Claim 20
Dependent Claim
20 words
A process according to claim 5 wherein the virus is HSV1, HSV2, EBV, cytomegalovirus, varicella/zoster virus or simian B virus.
Claim 21
Dependent Claim
46 words
An antigenic, immunogenic HSV2 subunit having 3 groups of viral directed glycoproteins, a first group of from about 110,000 to about 130,000 daltons, a second group of from about 83,000 to about 90,000 daltons and a third group of from about 55,000 to about 60,000 daltons.
Claim 22
Dependent Claim
46 words
An antigenic, immunogenic HSV2 subunit having 3 groups of viral directed glycoproteins, a first group of from about 110,000 to about 130,000 daltons, a second group of from about 83,000 to about 90,000 daltons and a third group of from about 55,000 to about 60,000 daltons.
Claim 23
Dependent Claim
15 words
A subunit according to claim 18 having about 6 major and about 5 minor polypeptides.
Claim 24
Dependent Claim
31 words
An antigenic, immunogenic HSV1 subunit having a first group of viral directed glycoproteins of about 123,000 molecular weight and a second group of viral directed glycoproteins of about 60,000 molecular weight.
Claim 25
Dependent Claim
31 words
An antigenic, immunogenic HSV1 subunit having a first group of viral directed glycoproteins of about 123,000 molecular weight and a second group of viral directed glycoproteins of about 60,000 molecular weight.
Claim 26
Dependent Claim
15 words
A subunit according to claim 20 having about 3 major and about 6 minor polypeptides.
References Cited (Backward Citations)
FR2300M
Cited
GB1140316A
Cited
US3452135A
Cited
US3651213A
Cited
US3897549A
Cited
US4140762A
Cited
US4020183A
Cited
EP0001365A1
Cited
US4374127A
Cited
US4391911A
Cited
US4235877A
Cited
US4341754A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-06-05 | 1987-12-05 | 1988-06-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-06-05 | 1991-12-05 | 1992-06-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-06-05 | 1995-12-05 | 1996-06-05 | $7700.00 | Window Closed / Lapsed |